Overview

Dimethylglycine (DMG) is a tertiary amino acid formed as an intermediate in the metabolism of choline to glycine. It participates in one-carbon metabolism by donating methyl groups, a process essential for DNA synthesis, neurotransmitter production, and the maintenance of healthy homocysteine levels. DMG is found in small amounts in foods such as beans, liver, and grains but is more commonly consumed as a dietary supplement.

Research into DMG has explored its potential as an immune modulator and physical performance enhancer. Some animal studies suggest that DMG supplementation can improve antibody responses and enhance the activity of natural killer cells and macrophages. In the realm of exercise physiology, DMG has been proposed to support oxygen utilization and reduce lactic acid accumulation, though human clinical evidence for significant ergogenic effects remains limited and inconsistent.

DMG is available as a supplement in tablet, capsule, and sublingual forms, with typical daily doses ranging from 125 to 500 mg. It is generally well tolerated with a favorable safety profile. DMG has also been explored as a supportive intervention for individuals with autism spectrum disorder, though results from controlled trials have been inconclusive, and further research is needed to clarify its therapeutic potential.

Mechanism of Action

"

One-Carbon Metabolism & Methyl Donation\n\nDimethylglycine (DMG) is a tertiary amino acid and intermediate in the choline oxidation pathway: choline -> betaine (trimethylglycine) -> dimethylglycine -> sarcosine -> glycine. DMG is produced when betaine-homocysteine methyltransferase (BHMT) transfers a methyl group from betaine to homocysteine, regenerating methionine. DMG thus serves as a marker and participant in the folate-independent arm of one-carbon metabolism (PMID: 15321801).\n\n

Mitochondrial Dehydrogenase Reaction\n\nDMG is further demethylated in the mitochondrial matrix by dimethylglycine dehydrogenase (DMGDH), a flavoprotein that transfers the methyl group to tetrahydrofolate (THF), generating 5,10-methylene-THF and sarcosine. This reaction directly links the choline catabolism pathway to the mitochondrial folate pool, supporting nucleotide biosynthesis and methylation reactions throughout the cell (PMID: 12586215).\n\n

Immune Modulation\n\nDMG supplementation has been shown to enhance both humoral and cell-mediated immune responses in animal models. It increases antibody production (IgM and IgG titers), enhances lymphocyte proliferation in response to mitogens, and augments natural killer (NK) cell cytotoxic activity. The proposed mechanism involves improved methylation-dependent immune cell signaling and enhanced mitochondrial ATP production in lymphocytes, supporting the energetic demands of clonal expansion (PMID: 7546278).\n\n

Oxygen Utilization & Exercise\n\nDMG is hypothesized to improve oxygen utilization at the cellular level by supporting mitochondrial electron transport through its role as an electron donor during DMGDH-catalyzed oxidation. This generates FADH2, which feeds electrons into the respiratory chain via electron-transfer flavoprotein (ETF), potentially enhancing aerobic energy production during physical exertion."

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Dimethylglycine (DMG)

Common Side Effects

• Generally very well-tolerated at standard doses (125-250 mg/day)
• Mild body odor changes (fishy or unusual smell) — related to trimethylamine production
• Gastrointestinal discomfort: mild nausea, stomach upset
• Insomnia or restlessness (some users report stimulant-like effects)
• Headache (infrequent)
• Hyperactivity in some children with autism (paradoxical excitatory response)

Serious Adverse Effects

• No serious adverse effects documented in published literature at standard supplemental doses
• Theoretical accumulation of trimethylamine in individuals with trimethylaminuria (TMAU / "fish odor syndrome")
• Long-term safety from controlled clinical trials is not established
• No hepatotoxicity, nephrotoxicity, or cardiovascular toxicity reported
• Animal studies using very high doses have not revealed significant toxicity

Contraindications

• Trimethylaminuria (TMAU) — DMG is metabolized to trimethylamine; may severely worsen symptoms
• Known hypersensitivity to DMG or related compounds
• Pregnancy and breastfeeding (insufficient data)
• Use caution in individuals with seizure disorders (some anecdotal reports of increased excitability, though evidence is mixed)

Drug Interactions

• May enhance the effects of other methyl donors (betaine, SAMe, folate, B12) — monitor for overmethylation symptoms (irritability, anxiety, insomnia)
• No well-documented drug interactions with prescription medications
• Theoretically may interact with anti-seizure medications if excitatory effects occur
• Potential additive effect with immune-stimulating supplements or medications
• No known CYP450 interactions

Population-Specific Considerations

• Athletes: Used for endurance and recovery; generally well-tolerated at 1-2 mg/kg/day
• Children with ASD: Mixed evidence; some report behavioral improvements, others paradoxical hyperactivity — monitor closely
• Elderly: No specific contraindications; may support immune function
• TMAU carriers: Avoid; may exacerbate trimethylamine accumulation
• Those on methyl donor protocols: Consider total methylation load when adding DMG to regimens with SAMe, folate, or betaine

Pharmacokinetic Profile